Subscribe To
Leap therapeutics to present updated data from part a of the distinguish study of dkn-01 plus tislelizumab and chemotherapy in gastric cancer patients at the 2023 asco annual meeting
19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient wit...
May 25, 2023, 5:10 pm
Shareholder investigation: halper sadeh llc investigates aqua, lptx, alr
NEW YORK, Feb. 05, 2023 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential vio...
February 5, 2023, 3:13 pm
Lifshitz law pllc announces investigations of atcx, cemi, lptx, and aqua
NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) — Atlas Technical Consultants, Inc. (NASDAQ: ATCX) Lifshitz Law PLLC announces an investigation into possib...
February 5, 2023, 1:01 am
Leap therapeutics to present new data from distinguish study of dkn-01 plus tislelizumab and waking study of dkn-01 plus tecentriq® at the esmo congress
Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding bench...
September 4, 2022, 6:05 pm
Ride on rising p/e investing with these 5 top-ranked stocks
Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Lea...
July 8, 2022, 9:20 am